NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics NASDAQ:NEO reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on year to $201.7 million. The company expects the full year’s revenue to be around $804 million, close to analysts’ estimates. Its non-GAAP profi…